193 related articles for article (PubMed ID: 28960310)
1. Novel targets for sensitizing breast cancer cells to TRAIL-induced apoptosis with siRNA delivery.
Thapa B; Bahadur Kc R; Uludağ H
Int J Cancer; 2018 Feb; 142(3):597-606. PubMed ID: 28960310
[TBL] [Abstract][Full Text] [Related]
2. Breathing New Life into TRAIL for Breast Cancer Therapy: Co-Delivery of pTRAIL and Complementary siRNAs Using Lipopolymers.
Thapa B; Kc R; Bahniuk M; Schmitke J; Hitt M; Lavasanifar A; Kutsch O; Seol DW; Uludag H
Hum Gene Ther; 2019 Dec; 30(12):1531-1546. PubMed ID: 31547718
[TBL] [Abstract][Full Text] [Related]
3. Roscovitine sensitizes breast cancer cells to TRAIL-induced apoptosis through a pleiotropic mechanism.
Ortiz-Ferrón G; Yerbes R; Eramo A; López-Pérez AI; De Maria R; López-Rivas A
Cell Res; 2008 Jun; 18(6):664-76. PubMed ID: 18458681
[TBL] [Abstract][Full Text] [Related]
4. Downregulation of Mcl-1 by daunorubicin pretreatment reverses resistance of breast cancer cells to TNF-related apoptosis-inducing ligand.
Oh B; Park S; Pak JH; Kim I
Biochem Biophys Res Commun; 2012 May; 422(1):42-7. PubMed ID: 22554523
[TBL] [Abstract][Full Text] [Related]
5. Enzymatically active cathepsin D sensitizes breast carcinoma cells to TRAIL.
Jancekova B; Ondrouskova E; Knopfova L; Smarda J; Benes P
Tumour Biol; 2016 Aug; 37(8):10685-96. PubMed ID: 26867770
[TBL] [Abstract][Full Text] [Related]
6. Aspirin sensitizes cancer cells to TRAIL-induced apoptosis by reducing survivin levels.
Lu M; Strohecker A; Chen F; Kwan T; Bosman J; Jordan VC; Cryns VL
Clin Cancer Res; 2008 May; 14(10):3168-76. PubMed ID: 18483385
[TBL] [Abstract][Full Text] [Related]
7. Surface TRAIL decoy receptor-4 expression is correlated with TRAIL resistance in MCF7 breast cancer cells.
Sanlioglu AD; Dirice E; Aydin C; Erin N; Koksoy S; Sanlioglu S
BMC Cancer; 2005 May; 5():54. PubMed ID: 15916713
[TBL] [Abstract][Full Text] [Related]
8. Mcl-1 mediates tumor necrosis factor-related apoptosis-inducing ligand resistance in human cholangiocarcinoma cells.
Taniai M; Grambihler A; Higuchi H; Werneburg N; Bronk SF; Farrugia DJ; Kaufmann SH; Gores GJ
Cancer Res; 2004 May; 64(10):3517-24. PubMed ID: 15150106
[TBL] [Abstract][Full Text] [Related]
9. RNAi silencing of the MEKK3 gene promotes TRAIL-induced apoptosis in MCF-7 cells and suppresses the transcriptional activity of NF-κB.
Guo SY; Liu SG; Liu L; Zhou XJ; Gu Y
Oncol Rep; 2012 Feb; 27(2):441-6. PubMed ID: 22020406
[TBL] [Abstract][Full Text] [Related]
10. Identification of novel molecular regulators of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced apoptosis in breast cancer cells by RNAi screening.
Garimella SV; Gehlhaus K; Dine JL; Pitt JJ; Grandin M; Chakka S; Nau MM; Caplen NJ; Lipkowitz S
Breast Cancer Res; 2014 Apr; 16(2):R41. PubMed ID: 24745479
[TBL] [Abstract][Full Text] [Related]
11. Simultaneously targeting bcl-2 and Akt pathways sensitizes nasopharyngeal carcinoma to tumor necrosis factor-related apoptosis-inducing ligand.
Li SS; Tang QL; Wang SH; Wang S; Yang XM
Cancer Biother Radiopharm; 2012 Feb; 27(1):88-95. PubMed ID: 21936689
[TBL] [Abstract][Full Text] [Related]
12. Bcl-xL inhibition by molecular-targeting drugs sensitizes human pancreatic cancer cells to TRAIL.
Hari Y; Harashima N; Tajima Y; Harada M
Oncotarget; 2015 Dec; 6(39):41902-15. PubMed ID: 26506422
[TBL] [Abstract][Full Text] [Related]
13. Silencing of prion protein sensitizes breast adriamycin-resistant carcinoma cells to TRAIL-mediated cell death.
Meslin F; Hamaï A; Gao P; Jalil A; Cahuzac N; Chouaib S; Mehrpour M
Cancer Res; 2007 Nov; 67(22):10910-9. PubMed ID: 18006836
[TBL] [Abstract][Full Text] [Related]
14. Polymeric delivery of siRNA for dual silencing of Mcl-1 and P-glycoprotein and apoptosis induction in drug-resistant breast cancer cells.
Aliabadi HM; Mahdipoor P; Uludağ H
Cancer Gene Ther; 2013 Mar; 20(3):169-77. PubMed ID: 23449477
[TBL] [Abstract][Full Text] [Related]
15. Repeated treatment with subtoxic doses of TRAIL induces resistance to apoptosis through its death receptors in MDA-MB-231 breast cancer cells.
Yoshida T; Zhang Y; Rivera Rosado LA; Zhang B
Mol Cancer Res; 2009 Nov; 7(11):1835-44. PubMed ID: 19843632
[TBL] [Abstract][Full Text] [Related]
16. Notch inhibition restores TRAIL-mediated apoptosis via AP1-dependent upregulation of DR4 and DR5 TRAIL receptors in MDA-MB-231 breast cancer cells.
Portanova P; Notaro A; Pellerito O; Sabella S; Giuliano M; Calvaruso G
Int J Oncol; 2013 Jul; 43(1):121-30. PubMed ID: 23686163
[TBL] [Abstract][Full Text] [Related]
17. Death receptor 4 (DR4) efficiently kills breast cancer cells irrespective of their sensitivity to tumor necrosis factor-related apoptosis-inducing ligand (TRAIL).
Kazhdan I; Marciniak RA
Cancer Gene Ther; 2004 Oct; 11(10):691-8. PubMed ID: 15354201
[TBL] [Abstract][Full Text] [Related]
18. Synergistic interactions of chemotherapeutic drugs and tumor necrosis factor-related apoptosis-inducing ligand/Apo-2 ligand on apoptosis and on regression of breast carcinoma in vivo.
Singh TR; Shankar S; Chen X; Asim M; Srivastava RK
Cancer Res; 2003 Sep; 63(17):5390-400. PubMed ID: 14500373
[TBL] [Abstract][Full Text] [Related]
19. Targeting cell spreading: a method of sensitizing metastatic tumor cells to TRAIL-induced apoptosis.
Phipps LE; Hino S; Muschel RJ
Mol Cancer Res; 2011 Mar; 9(3):249-58. PubMed ID: 21296861
[TBL] [Abstract][Full Text] [Related]
20. Down-regulation of HSP27 sensitizes TRAIL-resistant tumor cell to TRAIL-induced apoptosis.
Zhuang H; Jiang W; Cheng W; Qian K; Dong W; Cao L; Huang Q; Li S; Dou F; Chiu JF; Fang XX; Lu M; Hua ZC
Lung Cancer; 2010 Apr; 68(1):27-38. PubMed ID: 19540014
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]